Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
J Assist Reprod Genet ; 24(1): 17-22, 2007 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-17180469

RESUMO

PURPOSE: To analyze the results of our transferred embryos, especially those that "changed" their blastomere nuclearity from Multinucleated (MN) to Mono-nucleated during development. METHODS: Pregnancies where at least one MN embryo was transferred were retrospectively evaluated and categorized in order to record and follow-up on the ones that were implanted. Embryos were classified as normal (when all blastomeres were mono-nucleated on day one and two of development), corrected (multinucleated embryos on day one that became mono-nucleated on day two) and non-corrected (multinucleated either on day one, on day two or both days). RESULTS: There were 633 transfer cycles analyzed. Thirty-three percent (206) had at least one embryo with a MN blastomere at a given stage of development. Pregnancy and implantation rates were 29.0% and 19.0% for the group of exclusively mono-nucleated embryo transfers, and 28.6% and 15.8% for the group with at least one MN embryo transferred. The pregnancy outcome for "corrected" and "non-corrected" embryos could be corroborated unequivocally in only 9 cases, with an outcome of 8 and 4 normal babies, respectively. CONCLUSIONS: Because the amount of data analyzed is not satisfactorily large, differences were not significantly different; however, a trend may exist showing that normal at term pregnancies obtained from corrected embryos are more likely to occur than those from non-corrected embryos. Nuclear observation on a daily basis should be one of the strategies used to select the best embryos for transferring, to improve implantation rates and avoid multiple pregnancies.


Assuntos
Blastômeros/citologia , Núcleo Celular , Transferência Embrionária , Embrião de Mamíferos/citologia , Desenvolvimento Embrionário , Feminino , Humanos , Gravidez , Resultado da Gravidez
2.
Reprod Biomed Online ; 9(4): 370-1, 2004 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-15511330

RESUMO

A 40-year-old patient underwent intracytoplasmic sperm injection and assisted hatching, and a single embryo was transferred. Ultrasonography demonstrated a single gestational sac containing monochorionic tri-amniotic pregnancy. Several factors that have been implicated in the aetiology of monozygotic triple pregnancies after IVF appear to be present in this case. To avoid multiple pregnancies after IVF, it is time to have definite predictive factors for the occurrence of monozygotic multiple pregnancies as well as transferring only a single embryo.


Assuntos
Transferência Embrionária , Gravidez Múltipla , Trigêmeos , Adulto , Córion/anatomia & histologia , Transferência Embrionária/efeitos adversos , Feminino , Humanos , Masculino , Gravidez , Técnicas de Reprodução Assistida/efeitos adversos , Injeções de Esperma Intracitoplásmicas
3.
Rev. Fac. Med. (Caracas) ; 17(1): 25-30, ene.-jun. 1994. ilus
Artigo em Espanhol | LILACS | ID: lil-142365

RESUMO

En este estudio se presentan resultados obtenidos sobre la identificación, aislamiento y utilización de un antígeno T. cruzi específico de peso molecular 24/25 kDA ("Tc-24-25) de utilidad para el serodiagnóstico de la enfermedad de Chagas


Assuntos
Humanos , Masculino , Feminino , Anticorpos Monoclonais/isolamento & purificação , Doença de Chagas/diagnóstico , Testes Sorológicos/métodos , Trypanosoma cruzi
4.
Rev. Fac. Med. (Caracas) ; 17(1): 92-9, ene.-jun. 1994. ilus
Artigo em Espanhol | LILACS | ID: lil-142374

RESUMO

Los estudios realizados desde el punto de vista molecular, celular y organismico revelan que el Trypanosoma cruzi en su proliferación depende de la producción de esteroles endógenos. Cualquier intervención farmacológica que modifique esta ruta biosintética previene la proliferación del parásito, in vivo e in vitro. Además cuando se combinan estos agentes, ellos pueden tener acción sinergética sobre la proliferación del parásito, lo que permite pensar, que podría ser útil en el tratamiento de la Enfermedad de Chagas, sin efectos secundarios. Las combinaciones hasta ahora conocidas son el ketoconazol (Janssen) Lamisil (Sandoz) y el ketoconazol-Mevacor (Merk Sharp & Dohme). Otras combinaciones han sido evaluadas por nuestro grupo y la OMS, como el itraconazol (Janssen) que posee mayor actividad y menor toxicidad que el anterior, usándolo en combinación con la sinvastatina (Merk Sharp & Dohne) y la fluvastatina (Sandoz). Finalmente, las terapéuticas propuestas pueden ser útiles en el tratamiento de otras enfermedades parasitarias y algunas micosis sistémicas


Assuntos
Humanos , Masculino , Feminino , Anticolesterolemiantes , Doença de Chagas/terapia , Sinergismo Farmacológico , Técnicas In Vitro , Trypanosoma cruzi
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA